# Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer

> **NCT05188781** · — · COMPLETED · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 34 (actual)

## Conditions studied

- High-Grade Serous Ovarian Cancer

## Interventions

- **DRUG:** Pembrolizumab combined Anlotinib

## Key facts

- **NCT ID:** NCT05188781
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-04
- **Primary completion:** 2021-08-23
- **Final completion:** 2021-08-23
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2022-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05188781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05188781, "Pembrolizumab and Anlotinib in the Treatment of High-Grade Serous Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05188781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*